Glutathione Bioavailability: What Oral, Liposomal and IV Studies Found

LynxLab · 24 October 2026 · 9 min read

The human studies on oral, liposomal and intravenous glutathione from Witschi 1992 to Richie 2015, the skin-lightening claims, and the FDA warnings on IV drips.

Photo: Judy Beth Morris, Unsplash

Every argument about glutathione supplements eventually arrives at the same question: does any of it get in? The molecule is a tripeptide, the gut is lined with an enzyme that cuts it apart, and for twenty years the standard answer in pharmacology textbooks was no. Then a six-month trial in Pennsylvania said otherwise, and the debate has not settled since.

This explainer walks through the human studies on oral, liposomal and intravenous glutathione, what each one measured and what it found. It ends with the skin-lightening market that grew up around IV drips and the regulators who have warned against it. What glutathione does once it is inside a cell is covered separately in how the GSH/GSSG ratio is measured.

Why bioavailability is the first question

Glutathione is glutamate, cysteine and glycine joined by a gamma-glutamyl bond. That bond protects it from ordinary peptidases, but not from gamma-glutamyltransferase (GGT), an enzyme concentrated on the surface of intestinal and liver cells. GGT strips the glutamate off, and the remaining cysteinylglycine is split by dipeptidases.

The result is that swallowed glutathione tends to arrive in the bloodstream as its three component amino acids, not as the intact tripeptide. Cells then rebuild it from scratch, which they would do anyway from dietary protein. The question researchers have been testing since 1992 is whether any intact molecule survives that gauntlet, and whether the amino acids alone change tissue stores.

Witschi 1992: the study that set the sceptical view

The reference point for every later paper is a short study from the University of Bern. Witschi and colleagues gave seven healthy volunteers a single oral dose of 3 grams of glutathione and sampled plasma for 270 minutes.

Plasma glutathione, cysteine and glutamate did not rise significantly from their baselines of 6.2, 8.3 and 54 micromoles per litre. The authors concluded that "the systemic availability of glutathione is negligible in man" and that a single oral dose could not raise circulating levels to a clinically useful extent (Witschi et al., European Journal of Clinical Pharmacology, 1992).

Two limits of that study are worth stating. It measured plasma, where glutathione is scarce and short-lived, rather than red cells or tissue where most of it sits. And it was a single dose, so it could not detect slow accumulation.

Allen and Bradley 2011: four weeks, no change

The first randomised, placebo-controlled trial took a longer view. Jason Allen and Ryan Bradley at Bastyr University in Washington State enrolled 40 healthy adults and gave half of them oral glutathione, 500mg twice a day, for four weeks (Allen and Bradley, Journal of Alternative and Complementary Medicine, 2011).

They measured two urinary markers of oxidative damage, F2-isoprostanes and 8-hydroxy-2'-deoxyguanosine, and erythrocyte GSH, GSSG and their ratio by tandem liquid chromatography and mass spectrometry. Thirty-nine participants completed the trial.

Nothing moved. Neither urinary marker differed between groups at week four, and total, reduced and oxidised glutathione in red cells were unchanged. The authors concluded that oral glutathione produced no significant change in oxidative stress biomarkers in healthy adults.

Richie 2015: six months, 54 adults, stores rose

The trial that reopened the question came from John Richie's group at Penn State College of Medicine. It was randomised, double-blind and placebo-controlled, ran for six months, and enrolled 54 non-smoking adults at two daily doses, 250mg and 1,000mg (Richie et al., European Journal of Nutrition, 2015).

Blood glutathione rose at one, three and six months against baseline at both doses. At six months the high-dose group showed mean increases of 30 to 35% in erythrocytes, plasma and lymphocytes and 260% in exfoliated buccal cells, the cells lining the cheek. The low-dose group rose 17% in whole blood and 29% in erythrocytes.

The ratio of oxidised to reduced glutathione in whole blood fell in both dose groups at six months, and natural killer cell cytotoxicity more than doubled in the high-dose group at three months. Levels returned to baseline after a one-month washout.

The Richie trial does not overturn Witschi so much as measure something different. Witschi looked for intact molecule in plasma over hours. Richie looked at stores in cells over months. Both results can be true at once if the extra glutathione is being rebuilt inside cells from the amino acids the gut delivers.

Liposomal glutathione: a 2018 pilot and its caveats

Liposomal products wrap the tripeptide in a lipid shell, on the theory that it will be absorbed like a fat rather than digested like a protein. The same Penn State group tested that in a one-month pilot study published in the European Journal of Clinical Nutrition in 2018 (Sinha et al., European Journal of Clinical Nutrition, 2018).

Twelve healthy adults received 500mg or 1,000mg of liposomal glutathione a day. Levels were up within a week, with maximum increases of 40% in whole blood, 25% in erythrocytes, 28% in plasma and 100% in peripheral blood mononuclear cells at two weeks. Plasma 8-isoprostane fell 35% and the oxidised-to-reduced ratio fell 20%.

Three caveats sit on top of that. Twelve subjects is a pilot, not a trial, and there was no placebo arm. The two doses could not be told apart, which the authors attribute to the small sample. And the study was funded by Researched Nutritionals, the company that makes the liposomal product tested, a conflict the paper declares.

Whether liposomes outperform plain glutathione has not been tested head to head in a controlled trial. Anyone who wants to buy glutathione for a comparative absorption study is working in open territory.

Intravenous glutathione: what the trials actually show

Injection bypasses the gut entirely, so bioavailability is not the issue. The same is true of reduced glutathione for research added straight to a cell culture medium. The issue in a person is whether a large dose in the bloodstream does anything, and what else arrives with it.

The best-known controlled trial is Robert Hauser's 2009 pilot in Parkinson's disease, published in Movement Disorders. Twenty-one patients were randomised to intravenous glutathione, 1,400mg three times a week for four weeks, or placebo (Hauser et al., Movement Disorders, 2009). The infusions were well tolerated with no safety concerns. There was no significant difference in Parkinson's rating scores, and the authors described only "the possibility of a mild symptomatic effect" needing a larger study.

The only licensed use of intravenous glutathione anywhere is narrow. The Philippine Food and Drug Administration approves it as an adjunct to cisplatin chemotherapy, to reduce the drug's nerve toxicity, and for nothing else. In the United States there is no approved glutathione drug product at all; what clinics infuse is compounded.

The skin-lightening claims and the regulators' response

Glutathione shifts melanin production from dark eumelanin towards lighter phaeomelanin by acting on tyrosinase, which is why it is sold as a skin lightener across South and South East Asia. Sidharth Sonthalia's 2016 review in the Indian Journal of Dermatology, Venereology and Leprology found three randomised controlled trials of oral or topical glutathione showing some lightening in sun-exposed skin, all short-term, and no published data at all for the intravenous form (Sonthalia, Daulatabad and Sarkar, Indian J Dermatol Venereol Leprol, 2016).

The Philippine FDA has issued two public warnings. The first, in May 2011, said the use of IV glutathione as a skin whitener was not approved and listed reported reactions from rashes to Stevens-Johnson syndrome, thyroid disturbance and suspected kidney failure. The second, Advisory 2019-182, repeated that no clinical trial had evaluated injectable glutathione for skin lightening, that no injectable product was approved for the purpose, and that risks included liver, kidney and nerve toxicity and infection from unsterile administration (FDA Advisory No. 2019-182, Food and Drug Administration Philippines, 2019).

The US FDA's concern has been contamination rather than efficacy. On 27 August 2026 it reported at least 30 patients who fell ill after intravenous glutathione compounded from a single lot of dietary-supplement-grade powder, with fever, chills, shock-like symptoms and hospitalisations consistent with endotoxin exposure, and noted two Texas pharmacy recalls (FDA reminds compounders not to use dietary supplement grade glutathione for injectables, FDA, 2026). The agency had issued the same warning in 2019 after seven patients at one clinic reacted to a different supplier's powder.

That history is the reason grade matters. Material labelled as a dietary supplement is not tested to injectable endotoxin limits. Research material should come with its own analysis so a laboratory knows what it is working with. UK buyers comparing glutathione uk listings should look for that batch certificate before anything else.

LynxLab stocks glutathione 1500mg vials for research use at £38.99, tested to 99% purity with the lab reports on the product page.

Frequently asked questions

Is oral glutathione absorbed?

The 1992 Witschi study found no rise in plasma glutathione after a single 3g dose. The 2015 Richie trial found red cell and lymphocyte glutathione rose 30 to 35% after six months of daily 1,000mg. Both are consistent with the gut breaking glutathione into amino acids that cells then use to rebuild it.

Is liposomal glutathione better than regular glutathione?

One 2018 pilot in 12 people, funded by the manufacturer and without a placebo group, found blood glutathione rose within a week. No controlled trial has compared liposomal and plain oral glutathione directly, so the question is open.

Does IV glutathione whiten skin?

No clinical trial has tested it. The Philippine FDA has warned against the practice twice, in 2011 and 2019, and the US FDA reported at least 30 endotoxin reactions from compounded IV glutathione in August 2026. The only approved intravenous use anywhere is as an adjunct to cisplatin chemotherapy in the Philippines.

What is the difference between reduced glutathione and L-glutathione?

They are the same molecule. "Reduced" refers to the GSH form with its free thiol group, as opposed to oxidised GSSG, and "L" is the natural stereochemistry of its amino acids. Research listings for l-glutathione uk and for reduced glutathione both describe GSH, and the lab report should confirm how much of the batch is in the reduced form.

Sources

Research use only

Glutathione from LynxLab

1500mg vials from £38.99. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy Glutathione